Trials / Completed
CompletedNCT01366326
Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects
A Multiple-Dose, Open-Label Study to Evaluate the Pharmacokinetics of MNTX in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
MNTX 1109 is a single center, open label study, composed of normal healthy adult subjects to evaluate the PK of MNTX and its metabolites administered once daily as a subcutaneous (SC) injection for a period of seven days. Blood samples will be obtained at screening and for drug concentration data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylnaltrexone bromide | Subcutaneous MNTX |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2011-06-06
- Last updated
- 2019-11-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01366326. Inclusion in this directory is not an endorsement.